Engineering a Novel Antibody-Peptide Bispecific Fusion Protein Against MERS-CoV

Engineering a Novel Antibody-Peptide Bispecific Fusion Protein Against MERS-CoV

Li-li WANG, Jiyan Xu, Yu Kong, Ruiying Liang, Wei Li, Jinyao Li, Jun Lu, Dimiter S. Dimitrov, Fei Yu, Yan-Ling Wu, Tianlei Ying

In recent years, tremendous efforts have been made in the engineering of bispecific or multi-specific antibody-based therapeutics by combining two or more functional antigen-recognizing elements into a single construct. However, to the best of our knowledge there has been no reported cases of effective antiviral antibody-peptide bispecific fusion proteins. We previously developed potent fully human monoclonal antibodies and inhibitory peptides against Middle East Respiratory Syndrome Coronavirus (MERS-CoV), a novel coronavirus that causes severe acute respiratory illness with high mortality. Here, we describe the generation of antibody-peptide bispecific fusion proteins, each of which contains an anti-MERS-CoV single-chain antibody m336 (or normal human IgG1 CH3 domain as a control) linked with, or without, a MERS-CoV fusion inhibitory peptide HR2P. We found that one of these fusion proteins, designated as m336 diabody-pep, exhibited more potent inhibitory activity than the antibody or the peptide alone against pseudotyped MERS-CoV infection and MERS-CoV S protein-mediated cell-cell fusion, suggesting its potential to be developed as an effective bispecific immunotherapeutic for clinical use.

2019

MERS-CoV, MAbs, polypeptides, bispecific, Immunotherapeutics

DOI: 10.3390/antib8040053

Antibodies

MDPI AG

Immunologic diseases. Allergy

EN